ALLMedicine™ Acute Lymphoblastic Leukemia Center
Research & Reviews 7,962 results
https://doi.org/10.1186/s12913-022-08201-0
BMC Health Services Research; Beauchemin M, Santacroce SJ et. al.
Jun 29th, 2022 - The study purpose is to describe trajectories of financial distress for parents of children (ages 1-14.9 years) with newly diagnosed acute lymphoblastic leukemia (ALL). The secondary aim is to identify multilevel factors (child, parent, household,...
https://doi.org/10.1186/s13046-022-02421-2 10.3322/caac.21590 10.1053/sonc.2002.33531 10.1634/theoncologist.2007-0228 10.3389/fimmu.2018.02134 10.1158/2159-8290.CD-17-1033 10.1182/blood-2017-06-740944 10.1309/74R4TB90BUWH27JX 10.3389/fimmu.2018.02722 10.1517/13543784.2014.889681 10.1016/j.clml.2018.12.013 10.1038/nrclinonc.2016.36 10.1182/blood-2011-04-348540 10.1056/NEJMoa1215134 10.1056/NEJMoa1407222 10.1056/NEJMoa2024850 10.1016/j.ymthe.2017.04.024 10.3324/haematol.2015.137620 10.1182/blood.2020004918 10.1038/leu.2015.123 10.1186/1479-5876-10-29 10.1038/s41389-020-00257-z 10.4049/jimmunol.174.5.2687 10.1016/S1074-7613(00)80353-2 10.18632/oncotarget.27508 10.3109/10428194.2011.603449 10.1016/j.leukres.2013.03.010 10.1634/theoncologist.2017-0229 10.1309/3G1XDX0DVHBNVKB4 10.1111/j.1365-2141.2007.06526.x 10.1182/blood-2017-07-794214 10.3324/haematol.2018.192757 10.1038/sj.leu.2403262 10.1007/s00277-015-2359-2 10.1056/NEJMc1605684 10.1080/2162402X.2016.1217374 10.1056/NEJM199710093371501 10.1073/pnas.0400053101 10.1182/bloodadvances.2021005220 10.1007/s12185-009-0295-4
Journal of Experimental & Clinical Cancer Research : CR; Wang X, Yu X et. al.
Jun 29th, 2022 - Lymphoid neoplasms, including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and NK/T cell neoplasms, are a major cause of blood cancer morbidity and mortality. CD38 (cyclic ADP ribose hydrolase) is a transmembrane glycoprotein expressed on th...
https://doi.org/10.1158/2326-6066.CIR-21-0626
Cancer Immunology Research; Im NG, Guillaumet-Adkins A et. al.
Jun 28th, 2022 - Chimeric-antigen receptor (CAR) T-cell therapy has led to tremendous successes in the treatment of B-cell malignancies. However, a large fraction of treated patients relapse, often with disease expressing reduced levels of the target antigen. Here...
https://doi.org/10.1080/07357907.2022.2095397
Cancer Investigation; Singh K, Kumari S et. al.
Jun 28th, 2022 - Human leukemic T cells show decreased surface CD5 (sCD5) and increased cytoplasmic CD5 (cCD5). When we examined their expressions in the Jurkat T cells, it showed increased sCD5 and decreased cCD5, which is in sharp contrast with the pattern of CD...
https://doi.org/10.1080/10428194.2022.2090550
Leukemia & Lymphoma; Xu GF, Liu LM et. al.
Jun 25th, 2022 - Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subtype of ALL. We retrospectively studied 70 cases with Ph-like ALL and here present the largest study of CAR-T cell treatment and haplo-HSCT for this leukemia...
Guidelines 4 results
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.
Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.
Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...
https://doi.org/10.6004/jnccn.2017.0147
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.
Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...
https://doi.org/10.1016/j.bbmt.2011.12.585
Biology of Blood and Marrow Transplantation : Journal of ... Oliansky DM, Camitta B et. al.
Jan 3rd, 2012 - Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. T...
Drugs 124 results see all →
Clinicaltrials.gov 930 results
https://clinicaltrials.gov/ct2/show/NCT02315612
Jun 24th, 2022 - Background: Adoptive cellular therapy with T cells genetically modified using viral-based vectors to express chimeric antigen receptors targeting the CD19 molecule have demonstrated dramatic clinical responses in patients with acute lymphoblastic ...
https://clinicaltrials.gov/ct2/show/NCT04815356
Jun 24th, 2022 - Background Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias. Most cases of HCL respond well to purine analog chemotherapy and harbor BRAF V600E mutation that can be considered for targeted treatment at ...
https://clinicaltrials.gov/ct2/show/NCT00136435
Jun 24th, 2022 - This study has four treatment phases: 1) induction, 2) central nervous system therapy, 3) intensification, and 4) continuation. The induction phase lasts one month and eight drugs are used during this phase of treatment. The drugs are administered...
https://clinicaltrials.gov/ct2/show/NCT00400946
Jun 24th, 2022 - RISK CLASSIFICATION: Patients received were classified into initial risk groups defined as: High Risk (HR) High risk patients had any of the following features: age 10 years and older, a white blood cell count of 50 000 cells per μL or higher, ini...
https://clinicaltrials.gov/ct2/show/NCT02447718
Jun 24th, 2022 - Rationale and Aims: Children with acute lymphoblastic leukemia (ALL) have evidence of persistent immunosuppression following chemotherapy and may experience waning of immunity to vaccines received prior to treatment. There is no standard of care i...
News 1,279 results
https://www.onclive.com/view/car-t-cell-therapy-may-represent-a-new-option-in-medullary-thyroid-cancer
May 5th, 2022 - Investigators at the Perelman School of Medicine at the University of Pennsylvania (Penn) have recently initiated a clinical trial evaluating a novel CAR T-cell therapy in an effort to fill an unmet need for systemic treatment for patients with ad...
https://www.medscape.com/viewarticle/973361
May 3rd, 2022 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Donor hematopoietic stem cell infusions (DSIs) improve the efficacy of CAR T-cell therapy and overall survival for...
https://www.onclive.com/view/microbiota-modulation-offers-hope-of-expanding-the-benefits-of-immunotherapy
Apr 28th, 2022 - Although the microorganisms colonizing our bodies have long been linked to human health and various disease states, an understanding of the potential impact of the microbiota on cancer has just begun to emerge in the past 20 years. Novel strategie...
https://www.onclive.com/view/car-nk-cell-therapies-show-preliminary-safety-and-efficacy-in-aml-non-hodgkin-lymphoma
Apr 25th, 2022 - The novel allogeneic CAR-engineered natural killer (NK) cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia (AML) and non-Hodgkin ...
https://www.onclive.com/view/dr-akbar-on-the-efficacy-of-monoclonal-antibodies-across-various-trials-in-r-r-all
Apr 25th, 2022 - Usman Ali Akbar, MD, research coordinator, Division of Infectious Diseases, the University of Louisville, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leuke...